Stevanato Group S.p.A.

STVN Healthcare Medical Instruments & Supplies

Stevanato Group S.p.A.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 12.3% from fiscal 2024.

Revenue
+5.91%
EPS
+17.5%
Free cash flow
+4,089.9%
Total debt
+2.85%

Quarter to September 2026, against a year earlier

13.51 0.30 +2.27%
Market cap
$3.6B
P/E
22.4×
Fwd P/E
30.2×
Dividend yield
0.48%
F-score
5/9
Altman Z
4.48
Beneish M
−2.79
Dividend safety
63/100

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Revenue

+8 more quarters

399.57 320.19 351.14 375.30
Revenue Growth
13.07% 18.45% 10.46% 5.91%
Gross Profit
122.77 87.99 100.94 109.30
Operating Income
79.86 45.34 45.40 69.45
EBT
75.15 45.93 44.32 68.55
Income after Tax
54.40 32.80 26.69 48.16
Net Income Common
54.41 32.81 26.69 48.16
EPS (Diluted)
0.20 0.12 0.09 0.18
Shares (Diluted, Weighted)
272.96 273.02 273.04 273.14
Gross Margin
30.73% 27.48% 28.75% 29.12%
EBIT Margin
19.99% 14.16% 12.93% 18.51%
Net Profit Margin
13.62% 10.25% 7.60% 12.83%
EBITDA
105.28 74.19 73.34 98.34
EBIT
79.86 45.34 45.40 69.45

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 5 Nov 2026